Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study

被引:2
|
作者
Xu, Chuancai [1 ]
He, Zhisong [2 ]
Lei, Wei [1 ]
Chen, Li [3 ]
Shen, Dan [1 ]
Wang, Xiaofei [1 ]
Xu, Deyu [4 ]
Xu, Ying [3 ]
Huang, Jian'an [1 ]
机构
[1] Soochow Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, 899 Pinghai St, Suzhou 215006, Peoples R China
[2] Soochow Univ, Dept Cardiol, Affiliated Hosp 1, 899 Pinghai St, Suzhou 215006, Peoples R China
[3] Soochow Univ, Dept Infect Dis, Affiliated Hosp 1, 899 Pinghai St, Suzhou 215006, Peoples R China
[4] Soochow Univ, Dept Nephrol, Affiliated Hosp 1, 899 Pinghai St, Suzhou 215006, Peoples R China
关键词
SARS-CoV-2; Breakthrough infection; Inactivated vaccine; Viral RNA shedding; SARS-CoV-2-specific IgG; SARS-CoV-2-specific IgM; INFECTIONS;
D O I
10.1186/s12879-022-07808-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. Methods We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People's Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. Results The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5-14] days) and PV (13 [IQR, 9-16.75] days) groups than in the UV group (15 [IQR, 11.75-17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08-63.59] and 0.3 S/co [IQR, 0.05-2.29], respectively) and PV (0.68 S/co [IQR, 0.14-28.69] and 0.12 S/co [0.03-5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03-0.47] and 0.04 S/co [IQR, 0.02-0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively). Conclusions Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects
    Cristiano, Antonio
    Nuccetelli, Marzia
    Pieri, Massimo
    Sarubbi, Serena
    Pelagalli, Martina
    Calugi, Graziella
    Tomassetti, Flaminia
    Bernardini, Sergio
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [42] Associations of HLA Polymorphisms with Anti-SARS-CoV-2 Spike and Neutralizing Antibody Titers in Japanese Rheumatoid Arthritis Patients Vaccinated with BNT162b2
    Higuchi, Takashi
    Oka, Shomi
    Furukawa, Hiroshi
    Tohma, Shigeto
    VACCINES, 2023, 11 (02)
  • [43] A Study of Factors that Impact the Production of Anti-SARS-CoV-2 Antibodies in Patients with Covid-19
    Hussein, Nawfal R.
    Balatay, Amer
    Mohammad, Ameen M.
    Dhama, Kuldeep
    Rasheed, Narin A.
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2022, 8 (05): : 323 - 326
  • [44] Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study
    Golec, Marlena
    Zembala-John, Joanna
    Fronczek, Martyna
    Konka, Adam
    Bochenek, Aneta
    Wystyrk, Karolina
    Botor, Hanna
    Zalewska, Marzena
    Chrapiec, Martyna
    Kasperczyk, Slawomir
    Brzoza, Zenon
    Buldak, Rafal J.
    PLOS ONE, 2023, 18 (06):
  • [45] Exploratory study of antibody titers against SARS-CoV-2 using an indirect immunoperoxidase assay in COVID-19 patients and vaccinated volunteers
    Katoh, Shungo
    Yasuda, Ikkoh
    Kitakawa, Kazuhiro
    Hamaguchi, Sugihiro
    Sando, Eiichiro
    TROPICAL MEDICINE AND HEALTH, 2024, 52 (01)
  • [46] Therapeutic plasma exchange decreases plasma anti-SARS-CoV-2 spike IgG without increasing the proximate incidence of COVID-19
    Sullivan, Jensyn Cone
    Conklin, Steven E.
    Conrad, Stephanie
    Horowitz, Coby
    Diethelm, Mark
    Comenzo, Raymond
    JOURNAL OF CLINICAL APHERESIS, 2023, 38 (06) : 721 - 726
  • [47] The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19
    Lysek-Gladysinska, Malgorzata
    Starz, Magdalena
    Borowiec-Sek, Agnieszka
    Sufin, Iwona
    Wieczorek, Anna
    Chrapek, Magdalena
    Zarebska-Michaluk, Dorota
    Sufin, Patrycja
    Gluszek, Stanislaw
    Adamus-Bialek, Wioletta
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 145 - 160
  • [48] Duration of viral shedding in patients with COVID-19 and the redetectable positive cases with SARS-CoV-2: A hospital experience
    Al Qahtani, A. A.
    Bin Rasheed, A. M.
    Al Abood, A.
    Selim, Mohie E.
    Al Khalifah, A. K.
    Aurkmany, A.
    Al-Odayani, A.
    Te, M. C.
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (06) : 2461 - 2467
  • [49] Seroprevalence of anti-SARS-CoV-2 IgM and IgG and COVID-19 vaccine uptake in healthy volunteers in Nairobi, Kenya: a cross-sectional study
    Otindo, Agnes Muhonja
    Ndombi, Eric M.
    Theuri, Martin
    Muturi, Margaret
    Thamaini, Peris
    Ogutu, James
    Onsongo, Lister
    Madete, June K.
    Ofula, Victor
    Gitau, Samuel
    Mwangi, Gladys
    Okemo, Paul
    FRONTIERS IN VIROLOGY, 2024, 4
  • [50] Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients
    Fujigaki, Hidetsugu
    Inaba, Masato
    Osawa, Michiko
    Moriyama, Saya
    Takahashi, Yoshimasa
    Suzuki, Tadaki
    Yamase, Kenya
    Yoshida, Yukihiro
    Yagura, Yo
    Oyamada, Takayoshi
    Takemura, Masao
    Doi, Yohei
    Saito, Kuniaki
    JOURNAL OF IMMUNOLOGY, 2021, 206 (10): : 2393 - 2401